CEF2, Influenza Virus PA (46-54) – 1 mg

Overview

CEF2, Influenza Virus PA (46-54) is a highly specialized peptide derived from the RNA polymerase subunit of the influenza virus. This specific HLA-A*0201 restricted epitope plays a crucial role in immunological studies and vaccine development, allowing researchers to better understand the mechanisms of the influenza virus. With applications in both diagnostic and therapeutic research, this peptide is essential for those working in virology, immunology, and related fields.

Key Features

• Derived from the influenza virus RNA polymerase subunit.
• HLA-A*0201 restricted epitope, important for T-cell activation.
• High purity and stability for reliable experimental results.
• Available in a convenient 1 mg format, ideal for multiple applications.
• Compatible with various assays and peptide-based studies.

Specifications

FAQ

What are the applications of CEF2, Influenza Virus PA (46-54)?

This peptide is primarily used in immunological research, including T-cell studies and vaccine development. Its specific sequence allows it to induce responses in HLA-A*0201 positive individuals, making it suitable for understanding immune responses to influenza.

How should I store this peptide?

To maintain its integrity, store the peptide in a cool, dry place, preferably at -20°C. Avoid repeated freeze-thaw cycles to preserve its stability.

Is this peptide suitable for in vivo studies?

While CEF2, Influenza Virus PA (46-54) is primarily designed for in vitro studies, some researchers may explore its potential in in vivo applications with the appropriate safety and ethical considerations in mind.

For a wider range of peptides, check out our full selection of peptides and explore other relevant products like our PKG substrate or Autocamtide-2. Investing in high-quality peptides like CEF2 ensures the reliability of your research and experimentation.

Related Products

• CREBtide [KRREILSRRPSYR], 5-FAM labeled